PARP1 and neoplasm: Similarly, PARP or CHK1 inhibition increases tumor-cell PD-L1 expression, triggering pronounced CD8+ T-cell infiltration and robust antitumor activity; CD8+ T-cell depletion completely abrogates this synergy, confirming their essential role in the combined DDR inhibitor/PD-L1 strategy (88).